This milestone validates the facility’s quality systems and manufacturing controls following a $38 million expansion finalized in 2023. The site now hosts advanced analytical laboratories and chemical development suites, specifically optimized to handle lower-volume production runs. With reactor capacities reaching 2,000 liters, the facility is positioned to support orphan drugs, precision medicines, and other highly specialized therapies designed for smaller patient populations.
Cambrex High Point Facility Cleared for Global Commercial Drug Production
The Cambrex manufacturing plant in High Point, North Carolina, has secured regulatory approval from the FDA, Japan’s PMDA, and Australia’s TGA. This triple-clearance marks the site’s transition from clinical testing to a full-scale commercial hub capable of supplying active pharmaceutical ingredients across three major international markets.
Chief Executive Officer Thomas Loewald noted that the site’s design addresses a growing industry demand for flexible, small-scale commercial manufacturing. By integrating these capabilities, Cambrex now offers a streamlined pipeline that carries customer programs from initial development through long-term market supply. This expansion strengthens the company's North American footprint, providing a bridge between early-stage innovation and final product delivery for clients worldwide.
Comments (0)
No comments yet. Be the first!